skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Highlights in this white paper include:

This paper evaluates the methods manufacturers pursued in response to the swine flu pandemic 0f 2009/2010. It includes an analysis of alternate manufacturing methods and routes of administration, encompassing approved vaccines and trial metrics, to identify how manufacturers addressed these issues and how effective they have been. 

 

  • Companies developing cell culture manufactured influenza vaccines
  • Status of trivalent and quadrivalent vaccines including manufacturing processes and delivery routes
  • Current landscape in quadivalent vaccine development
  • Intradermal and subcutaneous influenza vaccine trials by phase
  • How processes surrounding influenza production have changed since the 2009/10 H1N1
    influenza pandemic, and what this tells us about how manufacturers are positioned to deal with new influenza strains
influenza vaccine landscape whitepaper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: